文献速递肝病

从NASH起源到代谢性脂肪肝病的未来

From the origin of NASH to the future of metabolic fatty liver disease.
PubMed 文献 · Gut · 2021-02-25

本文综述了非酒精性脂肪性肝病(NAFLD)从19世纪模糊疾病实体到当今最常见肝病的近两百年临床研究历程,重点梳理了NASH命名、组织学特征及2005年NASH临床研究网络评分系统的确立,并指出2021年肝活检仍是可靠评估NASH和早期纤维化的唯一诊断方法,但无创检测和分子分型研究正在增加。

要点

  • NAFLD已成为全球最常见的慢性肝病,其定义和分类历经近两百年演变。
  • 2005年NASH临床研究网络评分是首个全球接受的NAFLD分级分期系统,至今仍用于半定量主要组织学特征。
  • 2021年肝活检仍是可靠评估NASH和早期纤维化的唯一诊断方法,无创检测和分子分型是未来方向。

核心结论

  • NAFLD从19世纪未知起源的模糊疾病实体演变为当今最常见且研究最活跃的肝病,其病理和分子特征的认识对临床管理和研究至关重要。

研究设计与样本

  • 本文为综述,回顾了从19世纪至今近两百年关于NAFLD的临床研究文献。

主要发现

  • 直到1950年代,酒精相关肝病与NAFLD的临床区分仍不常见,可能导致了NAFLD作为代谢性疾病实体被长期延迟接受。
  • 「脂肪性肝炎」一词最早出现于1962年,而「非酒精性脂肪性肝炎」(NASH)于1980年提出,并定义了至今仍有效的组织病理学特征。
  • 2005年NASH临床研究网络评分是首个全球接受的NAFLD全谱系分级和分期系统,仍用于半定量主要组织学特征。
  • 2021年肝活检仍是唯一能可靠评估NASH和早期纤维化存在的诊断方法,但无创检测和NAFLD亚型分子分类的研究不断增加。

临床怎么用

  • 临床管理中应认识NAFLD作为代谢性疾病实体的历史演变,并依据现行组织学评分系统(如2005年NASH临床研究网络评分)进行半定量评估。
  • 当前肝活检仍是可靠评估NASH和早期纤维化的唯一诊断方法,但应关注无创检测和分子分型的发展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-alcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease worldwide. Understanding the pathological and molecular hallmarks from its first description to definitions of disease entities, classifications and molecular phenotypes is crucial for both appropriate clinical management and research in this complex disease. We provide an overview through almost two hundred years of clinical research from the beginnings as a nebulous disease entity of unknown origin in the 19th century to the most frequent and vigorously investigated liver disease today. The clinical discrimination between alcohol-related liver disease and NAFLD was uncommon until the 1950s and likely contributed to the late acceptance of NAFLD as a metabolic disease entity for long time. Although the term 'fatty liver hepatitis' first appeared in 1962, it was in 1980 that the term 'non-alcoholic steatohepatitis' (NASH) was coined and the histopathological hallmarks that are still valid today were defined. The 2005 NASH Clinical Research Network scoring was the first globally accepted grading and staging system for the full spectrum of NAFLD and is still used to semiquantify main histological features. In 2021, liver biopsy remains the only diagnostic procedure that can reliably assess the presence of NASH and early fibrosis but increasing efforts are made towards non-invasive testing and molecular classification of NAFLD subtypes.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Geier A, Tiniakos D, Denk H, et al. From the origin of NASH to the future of metabolic fatty liver disease. Gut. 2021. PMID: 33632710. doi:10.1136/gutjnl-2020-323202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。